A frequent deletion of chromosome 5q21 in advanced small cell and non-small cell carcinoma of the lung. 1994

S Hosoe, and K Ueno, and Y Shigedo, and I Tachibana, and T Osaki, and T Kumagai, and Y Tanio, and I Kawase, and Y Nakamura, and T Kishimoto
Department of Medicine III, Osaka University Medical School, Japan.

We have examined the deletion of the long arm of chromosome 5 (5q) in 59 cases of advanced lung cancer [39 cases of small cell lung cancer (SCLC), 20 cases of non-SCLC] using 12 restriction fragment length polymorphism markers on 5q. Of 59 lung cancer cases, 48 (81%) exhibited deletion at any portion of the 5q locus (loci). Such a high frequency of 5q deletion has not been reported in surgically resectable non-SCLC. One SCLC case showed a 5q deletion only in metastatic sites but not in the primary cancer. These data suggest that the inactivation of putative tumor-suppressor gene(s) on 5q may be a late event in the progression of lung cancer. There was no significant difference in frequency of 5q deletion between SCLC and non-SCLC. Compared to non-SCLC, however, SCLC usually showed widespread deletion on 5q. While the most frequent target region was estimated to be about 3-5 megabases at 5q21 around the adenomatous polyposis coli (APC) gene locus, some cases showed more telomeric deletion (5q33-35), suggesting that there are at least two different tumor-suppressor genes on 5q associated with the progression of lung cancer.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D012150 Polymorphism, Restriction Fragment Length Variation occurring within a species in the presence or length of DNA fragment generated by a specific endonuclease at a specific site in the genome. Such variations are generated by mutations that create or abolish recognition sites for these enzymes or change the length of the fragment. RFLP,Restriction Fragment Length Polymorphism,RFLPs,Restriction Fragment Length Polymorphisms
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D002872 Chromosome Deletion Actual loss of portion of a chromosome. Monosomy, Partial,Partial Monosomy,Deletion, Chromosome,Deletions, Chromosome,Monosomies, Partial,Partial Monosomies
D002874 Chromosome Mapping Any method used for determining the location of and relative distances between genes on a chromosome. Gene Mapping,Linkage Mapping,Genome Mapping,Chromosome Mappings,Gene Mappings,Genome Mappings,Linkage Mappings,Mapping, Chromosome,Mapping, Gene,Mapping, Genome,Mapping, Linkage,Mappings, Chromosome,Mappings, Gene,Mappings, Genome,Mappings, Linkage
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D004587 Electrophoresis, Agar Gel Electrophoresis in which agar or agarose gel is used as the diffusion medium. Electrophoresis, Agarose Gel,Agar Gel Electrophoresis,Agarose Gel Electrophoresis,Gel Electrophoresis, Agar,Gel Electrophoresis, Agarose
D005819 Genetic Markers A phenotypically recognizable genetic trait which can be used to identify a genetic locus, a linkage group, or a recombination event. Chromosome Markers,DNA Markers,Markers, DNA,Markers, Genetic,Genetic Marker,Marker, Genetic,Chromosome Marker,DNA Marker,Marker, Chromosome,Marker, DNA,Markers, Chromosome
D016147 Genes, Tumor Suppressor Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible. Antioncogenes,Cancer Suppressor Genes,Emerogenes,Genes, Cancer Suppressor,Genes, Growth Suppressor,Genes, Metastasis Suppressor,Growth Suppressor Genes,Metastasis Suppressor Genes,Tumor Suppressor Genes,Anti-Oncogenes,Genes, Onco-Suppressor,Oncogenes, Recessive,Tumor Suppressing Genes,Anti Oncogenes,Anti-Oncogene,Antioncogene,Cancer Suppressor Gene,Emerogene,Gene, Cancer Suppressor,Gene, Growth Suppressor,Gene, Metastasis Suppressor,Gene, Onco-Suppressor,Gene, Tumor Suppressing,Gene, Tumor Suppressor,Genes, Onco Suppressor,Genes, Tumor Suppressing,Growth Suppressor Gene,Metastasis Suppressor Gene,Onco-Suppressor Gene,Onco-Suppressor Genes,Oncogene, Recessive,Recessive Oncogene,Recessive Oncogenes,Suppressor Gene, Cancer,Suppressor Gene, Growth,Suppressor Gene, Metastasis,Suppressor Genes, Cancer,Suppressor Genes, Growth,Suppressor Genes, Metastasis,Tumor Suppressing Gene,Tumor Suppressor Gene
D017491 Genes, APC Tumor suppressor genes located in the 5q21 region on the long arm of human chromosome 5. The mutation of these genes is associated with familial adenomatous polyposis (ADENOMATOUS POLYPOSIS COLI) and GARDNER SYNDROME, as well as some sporadic colorectal cancers. Genes, Adenomatous Polyposis Coli,APC Gene,APC Genes,Gene, APC

Related Publications

S Hosoe, and K Ueno, and Y Shigedo, and I Tachibana, and T Osaki, and T Kumagai, and Y Tanio, and I Kawase, and Y Nakamura, and T Kishimoto
June 1999, International journal of cancer,
S Hosoe, and K Ueno, and Y Shigedo, and I Tachibana, and T Osaki, and T Kumagai, and Y Tanio, and I Kawase, and Y Nakamura, and T Kishimoto
August 2000, Molecular pathology : MP,
S Hosoe, and K Ueno, and Y Shigedo, and I Tachibana, and T Osaki, and T Kumagai, and Y Tanio, and I Kawase, and Y Nakamura, and T Kishimoto
January 1999, Pathology, research and practice,
S Hosoe, and K Ueno, and Y Shigedo, and I Tachibana, and T Osaki, and T Kumagai, and Y Tanio, and I Kawase, and Y Nakamura, and T Kishimoto
January 1999, Lung cancer (Amsterdam, Netherlands),
S Hosoe, and K Ueno, and Y Shigedo, and I Tachibana, and T Osaki, and T Kumagai, and Y Tanio, and I Kawase, and Y Nakamura, and T Kishimoto
June 1993, Genes, chromosomes & cancer,
S Hosoe, and K Ueno, and Y Shigedo, and I Tachibana, and T Osaki, and T Kumagai, and Y Tanio, and I Kawase, and Y Nakamura, and T Kishimoto
May 1997, Medicina clinica,
S Hosoe, and K Ueno, and Y Shigedo, and I Tachibana, and T Osaki, and T Kumagai, and Y Tanio, and I Kawase, and Y Nakamura, and T Kishimoto
September 1996, The Journal of pathology,
S Hosoe, and K Ueno, and Y Shigedo, and I Tachibana, and T Osaki, and T Kumagai, and Y Tanio, and I Kawase, and Y Nakamura, and T Kishimoto
November 1994, Cancer research,
S Hosoe, and K Ueno, and Y Shigedo, and I Tachibana, and T Osaki, and T Kumagai, and Y Tanio, and I Kawase, and Y Nakamura, and T Kishimoto
September 2011, Oncogene,
S Hosoe, and K Ueno, and Y Shigedo, and I Tachibana, and T Osaki, and T Kumagai, and Y Tanio, and I Kawase, and Y Nakamura, and T Kishimoto
July 1994, European journal of cancer. Part B, Oral oncology,
Copied contents to your clipboard!